Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
N. Catanzaro, Z. Wu, C. Fan, A. Schaefer, B. Yount, P. Bjorkman, R. S. Baric, M. C. Letko
The paper identifies ACE2 as a receptor for HKU5 coronaviruses from Pipistrellus abramus bats and investigates receptor tropism across merbecovirus clades.
bioRxiv · Mar 13, 2024 · PreprintMicrobiology
D. R. Martinez, F. Moreira, M. R. Zweigart, K. L. Gully, G. De la Cruz, A. Brown, L. E. Adams, N. Catanzaro, B. Yount, T. J. Baric, M. Mallory, H. Conrad, S. R. May, S. Dong, T. D. Scobey, , T. P. Sheahan
This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.
bioRxiv · Jun 27, 2023 · PreprintMicrobiology
A. C. Puhl, G. F. Gomes, S. Damasceno, E. J. Fritch, J. A. Levi, N. J. Johnson, F. Scholle, L. Premkumar, B. L. Hurst, F. LeeMontiel, F. P. Veras, S. S. Batah, A. T. Fabro, N. J. Moorman, B. Yount, , S. Ekins
This study tests FDA-approved kinase inhibitors against SARS-CoV-2 in vitro and in vivo, finding that vandetanib reduces inflammatory cytokines and mitigates lung inflammation in infected mice without reducing viral load.
bioRxiv · Dec 16, 2021 · PreprintImmunology
D. Martinez, A. Schaefer, S. Gobeil, D. Li, G. De la Cruz, R. Parks, X. Lu, M. Barr, K. Manne, K. Mansouri, R. J. Edwards, B. Yount, K. Anasti, S. Montgomery, X. Shen, , R. S. Baric
A broadly neutralizing antibody protects against multiple SARS-CoV and SARS-CoV-2 variants in mice by targeting a conserved epitope in the receptor-binding domain.
bioRxiv · Apr 27, 2021 · PreprintMicrobiology
D. R. Martinez, A. Schaefer, S. R. Leist, G. De la Cruz, A. West, E. N. Atochina-Vasserman, L. C. Lindesmith, N. Pardi, R. Parks, M. Barr, D. Li, B. Yount, K. O. Saunders, D. Weissman, B. Haynes, , R. S. Baric
This study shows chimeric spike mRNA vaccines protect mice against multiple Sarbecovirus strains, including variants and zoonotic viruses, better than standard SARS-CoV-2 vaccines.
bioRxiv · Mar 11, 2021Microbiology
A. C. Puhl, E. J. Fritch, T. R. Lane, L. V. Tse, B. Yount, C. Q. Sacramento, T. A. Tavella, F. T. M. Costa, S. Weston, J. Logue, M. Frieman, L. Premkumar, K. H. Pearce, B. L. Hurst, C. H. Andrade, , S. Ekins
This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.
bioRxiv · Dec 1, 2020Pharmacology & Toxicology
V. D. Menachery, K. Dinnon, B. Yount, E. T. McAnarney, L. Gralinski, A. E. Hale, R. Graham, T. D. Scobey, S. J. Anthony, L. Wang, B. S. Graham, S. H. Randell, W. I. Lipkin, R. S. Baric
This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.
bioRxiv · Sep 16, 2019Microbiology
V. D. Menachery, L. Gralinski, H. D. Mitchell, K. Dinnon, S. R. Leist, B. Yount, E. T. McAnarney, R. Graham, K. M. Waters, R. S. Baric
This study shows combining NSP16 mutation with other attenuating mutations creates a safe and effective live-attenuated coronavirus vaccine that works in aged mice and against heterologous challenges.
bioRxiv · Apr 28, 2018Microbiology